Latest Licensing Agreements News

Avecho Biotechnology has inked a decade-long exclusive licensing agreement with Sandoz for its pharmaceutical-grade cannabidiol capsule targeting insomnia in Australia, backed by a US$3 million upfront payment and promising milestone and royalty streams.

FirstWave Cloud Technology reported a mixed Q3 FY25 with declining cash reserves and ARR but secured a strategic AWS-funded partnership to accelerate cloud service adoption.

Novonix Limited advances its synthetic graphite production with Riverside commissioning and a new Chattanooga plant site, while winning a preliminary US trade case against Chinese imports and appointing Michael O’Kronley as CEO.

Argent BioPharma reports significant operational savings through manufacturing outsourcing, encouraging Phase IIb results for CimetrA®, and key regulatory approvals for cannabinoid therapies in Germany.

Patrys Limited advances its PAT-DX3 therapy development for inflammatory diseases while navigating cash flow challenges and pursuing partnerships to sustain operations.

Paradigm Biopharmaceuticals has secured ethics approval and appointed a CRO to launch its global phase 3 trial for injectable Pentosan Polysulfate Sodium in knee osteoarthritis, while initiating a substantial capital raising program.

Memphasys has initiated clinical utility testing of its Felix™ System in Brazil through a partnership with Laboratorio Androscience, aiming to establish a foothold in the rapidly growing Latin American IVF sector.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.

Cycliq Group Limited reported an 18% revenue increase to $2.9 million for the half-year ending December 2024, driven by higher transaction values and a revamped marketing strategy, despite a modest net loss of $211,214.

Avenira Limited has ended its licensing agreement with Aleees, freeing the company to focus on a phased development of its Wonarah Phosphate Project aimed at early revenue generation in late 2025.

Wellnex Life Limited has initiated a $22.1 million entitlement offer priced at $0.65 per share, coinciding with its proposed dual listing on the London Stock Exchange's AIM market, driven by strong UK institutional interest.

BTC Health has transformed its decade-long license agreement with Arna Pharma into an indefinite partnership, gaining royalties from Singapore and Malaysia sales and first rights to new pharmaceutical products in Australia and New Zealand.